<DOC>
	<DOC>NCT00522873</DOC>
	<brief_summary>The study is designed to investigate the safety of the investigational product for the lining of the uterus (endometrium).</brief_summary>
	<brief_title>Endometrial Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Postmenopausal women between 40 and 65 years of age with hormone therapy indication (symptoms and need for treatment) Nonhysterectomized women. Usual exclusion criteria for hormone therapy apply.</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Postmenopausal Symptoms e.g.</keyword>
	<keyword>Hot flushes</keyword>
	<keyword>Sweating episodes</keyword>
	<keyword>Vaginal dryness</keyword>
</DOC>